20:18:29 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Biovica International är ett läkemedelsbolag som inriktar sin forskning mot behandling av solida tumörer. Bolaget utvecklar metoder för mätning utav cellproliferation, där testet tas via blodprov. Proven analyserar risken för utvecklingen av enzymet tymidinkinas (TK), en enzym som har koppling till tumörers tillväxt. Bolaget grundades 2008 och har sitt huvudkontor i Uppsala.


2023-06-21 Bokslutskommuniké 2023
2023-03-16 Kvartalsrapport 2023-Q3
2022-12-15 Kvartalsrapport 2023-Q2
2022-11-07 Extra Bolagsstämma 2022
2022-09-01 Ordinarie utdelning BIOVIC B 0.00 SEK
2022-08-31 Årsstämma 2023
2022-08-31 Kvartalsrapport 2023-Q1
2022-06-16 Bokslutskommuniké 2022
2022-03-15 Kvartalsrapport 2022-Q3
2021-12-01 Kvartalsrapport 2022-Q2
2021-09-01 Ordinarie utdelning BIOVIC B 0.00 SEK
2021-08-31 Kvartalsrapport 2022-Q1
2021-08-31 Årsstämma 2022
2021-06-17 Bokslutskommuniké 2021
2021-03-18 Kvartalsrapport 2021-Q3
2020-12-03 Kvartalsrapport 2021-Q2
2020-08-28 Ordinarie utdelning BIOVIC B 0.00 SEK
2020-08-27 Årsstämma 2021
2020-08-27 Kvartalsrapport 2021-Q1
2020-06-12 Bokslutskommuniké 2020
2020-03-12 Kvartalsrapport 2020-Q3
2019-12-05 Kvartalsrapport 2020-Q2
2019-08-30 Ordinarie utdelning BIOVIC B 0.00 SEK
2019-08-29 Årsstämma 2020
2019-08-29 Kvartalsrapport 2020-Q1
2019-06-14 Bokslutskommuniké 2019
2019-05-02 Extra Bolagsstämma 2020
2019-03-21 Kvartalsrapport 2019-Q3
2018-12-13 Kvartalsrapport 2019-Q2
2018-08-31 Ordinarie utdelning BIOVIC B 0.00 SEK
2018-08-30 Årsstämma 2019
2018-08-30 Kvartalsrapport 2019-Q1
2018-06-15 Bokslutskommuniké 2018
2018-03-21 Kvartalsrapport 2018-Q3
2017-12-19 Kvartalsrapport 2018-Q2
2017-09-01 Ordinarie utdelning BIOVIC B 0.00 SEK
2017-08-31 Kvartalsrapport 2018-Q1
2017-08-31 Årsstämma 2018
2017-06-14 Bokslutskommuniké 2017


2022-06-13 10:00:00

Biovica today announced that the company’s blood test DiviTum®TKa was highlighted in an oral presentation on June 6th at the ASCO Annual Meeting from the BioItaLEE trial. The study results suggest that TKa can predict patients’ response to a CDK4/6 treatment.

The BioItaLEE trial is a Novartis sponsored Italian multicenter study of 287 patients with hormone receptor-positive (HR+), HER-2 negative advanced breast cancer (ABC) treated with first-line (1L) ribociclib (RIB) and letrozole (LET).

The study concluded that testing patient blood samples for both TKa and ctDNA at baseline [D0] and day 15 of first treatment cycle [D15] was prognostic for progression free survival, and predictive for treatment response in the study patient group (BioItaLEE trial; NCT03439046).

These findings suggest that combining the early dynamic assessment of both ctDNA and TKa can improve outcome prediction in patients treated with RIB+LET. Patients with ctDNA+/TKa+ are strongly enriched for non-responders. TKa and ctDNA capture different features of tumor biological activity and their combination warrants further evaluation in relation to other treatments, settings, and diseases.

“The drug class of CDK4/6 inhibitors have contributed to significant progress in treating metastatic breast cancer. However, not all patients benefit equally. Some patients experience early progression, while others will remain on therapy for many years. Analysis of ctDNA and serum TKa in patients give independent contributions to prognostic and predictive stratification of patients for response to treatment and therapy selection. Combining the two provides even stronger results. Our study provides important results that using these biomarkers can offer oncologists valuable information for making treatment decisions. Further studies are warranted,” said Grazia Arpino, M.D., PhD., Associate Professor, University of Naples Federico II, UNINA Department of Clinical Medicine and Surgery.

“The primary objective of the BioItaLEE study was to identify biomarkers of response in advanced breast cancer patients receiving 1st line ribociclib + letrozole. We are extremely pleased to see that on-treatment, circulating TKa levels are strongly correlated with patients’ response to ribociclib with a HR of 0.18 (p value <0.0001). On-treatment TKa values were also strongly predictive for a lack of response to ribocilib. Combining TKa values with ctDNA results improved the ability of both assays to identify non-responders even further. We have additional studies planned to follow-up on these impressive results. Our goal is to offer DiviTum®TKa as an affordable and convenient method to monitor treatment response in order to help oncologists make more informed treatment decisions for the benefit of their patients,” said Amy Williams, Ph.D., Global Head of Clinical Development and Medical Affairs at Biovica.

About DiviTum®TKa
DiviTum®TKa shows thymidine kinase activity (Tka), as a measure of cell proliferation, in serum or cell cultures. Thymidine kinase is an enzyme and in normal cells, the level is low. It rises, however, with cell division. DiviTum®TKa is an assay for measuring cell proliferation and all that is required of the patient is a simple blood test.